Mathilde joined Newmarket Strategy in 2025 following several years in HEOR and market access consulting. She has supported UK HTA submissions, advised on early evidence planning, and delivered value strategy projects involving payer, clinical, and internal stakeholder input across Europe.
Her experience includes facilitating cross-functional workshops, designing payer research, and supporting early launch planning across diverse therapeutic areas including oncology and rare diseases. Mathilde has co-authored several peer-reviewed publications in Value in Health and Orphanet.
She holds a Master of Public Health from Columbia University in New York.